Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TBXAS1 | P24557 | 8/20 | 0.35 |
| ▸ | CYP24A1 | Q07973 | 2/20 | 0.34 |
| ▸ | ADRB2 | P07550 | 3/20 | 0.32 |
| ▸ | ADRB1 | P08588 | 3/20 | 0.32 |
| ▸ | ADRB3 | P13945 | 3/20 | 0.32 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.32 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.32 |
| ▸ | GPR119 | Q8TDV5 | 1/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
| ▸ | LMNA | P02545 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL217823 | 0.81 | GPR119 (0.42) | TBXAS1CYP24A1L3MBTL1GPR119 | |
| SCHEMBL10359587 | 0.79 | TBXAS1 (0.36) | TBXAS1CYP24A1GPR119ALDH1A1LMNA | |
| SCHEMBL6094456 | 0.77 | CYP19A1 (0.38) | TBXAS1CYP24A1ADRB2ADRB1ADRB3 | |
| SCHEMBL27404668 | 0.76 | HSD17B10 (0.37) | TBXAS1CYP24A1ADRB2ADRB1ADRB3 | |
| SCHEMBL1199386 | 0.75 | AHR (0.36) | TBXAS1CYP24A1GPR119ALDH1A1LMNA | |
| SCHEMBL14158754 | 0.75 | GPR119 (0.35) | TBXAS1CYP24A1L3MBTL1GPR119ALDH1A1 | |
| SCHEMBL25392514 | 0.74 | CYP24A1 (0.35) | TBXAS1CYP24A1GPR119ALDH1A1LMNA | |
| SCHEMBL21982074 | 0.74 | ELANE (0.36) | TBXAS1CYP24A1GPR119ALDH1A1LMNA | |
| Iodide SCHEMBL18143129 | 0.74 | GPR119 (0.34) | TBXAS1CYP24A1L3MBTL1GPR119ALDH1A1 | |
| SCHEMBL29247460 | 0.74 | CYP24A1 (0.35) | TBXAS1CYP24A1GPR119ALDH1A1LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11799133-B2 | Non-aqueous electrolyte solution for lithium secondary battery and lithium secondary battery including the same | LG ENERGY SOLUTION, LTD. | 2023-10-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11799133-B2 | Non-aqueous electrolyte solution for lithium secondary battery and lithium secondary battery including the same | CACNA1S, PDHB, CACNA1F | TBXAS1 4114/4885CYP24A1 1038/4885ADRB2 2225/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.